Regeneron’s LAG-3 inhibitor fianlimab posted a phase 3 miss in melanoma, failing to outperform pembrolizumab (Keytruda) in a late-stage study. The result adds to recent clinical setbacks across the LAG-3 class, amplifying scrutiny on the strategy of combining LAG-3 blockade with established PD-1 therapy. Analysts highlighted the negative data as a further delay to the potential market impact of fianlimab-based regimens, with company expectations already challenged by prior failures in the past year. The trial outcome is likely to influence future program prioritization and partnership conversations. As Regeneron digests the readout, the next question is whether the company can pivot LAG-3 assets toward different combinations, biomarkers, or tumor contexts with stronger biologic alignment.